Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc.

NVCT·NASDAQ

$9.42

-0.95%
HealthcareBiotechnology

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

At a Glance

Live Snapshot
Market Cap$249.87M
EPS-1.3200
P/E Ratio-7.14
Earnings Date08/04/2026

nvct

Net Common Stock Issuance

Last Annual Value

29.11M

3-Year CAGR

-3%

5-Year CAGR

%

10-Year CAGR

%

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Competitors Analysis of Net Common Stock Issuance

NVCT · NASDAQ
CompanyNet Common Stock Issuance
CAGR 3Y
CAGR 5Y
CAGR 10Y
29.11M
76.6%N/AN/A 
49.98M
N/A489.8%N/A
126.12M
29.9%-5.7%N/A
PEPG logo
PepGen Inc.
NASDAQ:PEPG
107.98M
N/AN/AN/A
24.03M
N/AN/AN/A
0.00
N/AN/AN/A
12.00M
N/A31.0%N/A
0.00
N/AN/AN/A
2.58M
N/A-40.4%0.9%
61.08M
436.7%-3.7%N/A
224.18M
255.9%1.1%27.0%
Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Fair Value Envelope

NVCT · NASDAQ

Our analysis suggests that NVCT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.42, this represents a potential HIDDEN relative to our calculated worth for Nuvectis Pharma, Inc..

Intrinsic Value
Current Price: $9.42